How This Evidence Evolved
Acute Kidney Injury Prevention
From NAC Myths to Biomarker-Guided Bundles
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Follow-up studies, subgroup analyses, and real-world validation
AKI after abdominal surgery: bundle vs standard care, overall stages not different; TIMP-2×IGFBP7 0.3-2.0 subgroup 27.1% vs 48.0% (P=0.03)
30-day mortality after e-alert-detected community-acquired AKI: 25% (1,185 patients; no comparator)
Integration into clinical practice guidelines and recommendations
KDIGO 2012: stage AKI by creatinine/urine output; initial isotonic crystalloids in patients with or at risk of AKI, absent hemorrhagic shock (2B); protocol hemodynamic care for high-risk perioperative patients or septic shock (2C).
IV contrast CI-AKI risk is lower than thought. Saline prophylaxis for AKI or eGFR <30 without maintenance dialysis; assess fluid-overload risk. NAC not recommended. Do not avoid necessary contrast CT without a suitable alternative solely for CI-AKI risk.
CI-AKI prevention: IV isotonic sodium chloride or sodium bicarbonate rather than no volume expansion (1A); lowest possible contrast dose (not graded); oral NAC with IV isotonic crystalloids (2D)
Prophylaxis with IV normal saline indicated for AKI or eGFR <30 mL/min/1.73 m2 without maintenance dialysis; may be considered at eGFR 30-44 in individual high-risk circumstances; NAC not recommended (consensus, no trial endpoint)
Highlights of the KDIGO 2026 guideline for AKI/AKD
Current standard of care and ongoing research directions
Landmark Trials in This Story
Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine
Serum creatinine rise ≥44 μmol/L at 48 hours after contrast administration
Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine
Composite of death, dialysis, or persistent ≥50% creatinine increase at 90 days
Biomarker-guided Intervention to Prevent Acute Kidney Injury After Major Surgery: The Prospective Randomized BigpAK Study
AKI after abdominal surgery: bundle vs standard care, overall stages not different; TIMP-2×IGFBP7 0.3-2.0 subgroup 27.1% vs 48.0% (P=0.03)
The Use of Automated Electronic Alerts in Studying Short-Term Outcomes Associated with Community-Acquired Acute Kidney Injury
30-day mortality after e-alert-detected community-acquired AKI: 25% (1,185 patients; no comparator)
Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (Part 2).
CI-AKI prevention: IV isotonic sodium chloride or sodium bicarbonate rather than no volume expansion (1A); lowest possible contrast dose (not graded); oral NAC with IV isotonic crystalloids (2D)
Use of Intravenous Iodinated Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
Prophylaxis with IV normal saline indicated for AKI or eGFR <30 mL/min/1.73 m2 without maintenance dialysis; may be considered at eGFR 30-44 in individual high-risk circumstances; NAC not recommended (consensus, no trial endpoint)
[Highlights of the Kidney Disease: Improving Global Outcomes (KDIGO) 2026 clinical practice guideline for acute kidney injury/acute kidney disease].
Highlights of the KDIGO 2026 guideline for AKI/AKD
Evaluating Nephrocheck® as a Predictive Tool for Acute Kidney Injury.
Review of urinary TIMP-2×IGFBP7 for early AKI risk assessment and its integration with clinical care in high-risk settings.
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.